SyzOnc is developing cancer therapies for patients lacking effective treatment options. Leveraging an AI-savvy platform, we identify and validate next generation multi-modal targets in the solid tumor microenvironment that represent key signaling "nodes". We then identify small molecules that modulate these targets for further drug development.